L'intérêt à découvert pour Enerpac Tool Group donne aux investisseurs une idée du degré auquel les investisseurs parient sur la baisse de l'action de Enerpac Tool Group. Les données sur l'intérêt à découvert sont mises à jour toutes les deux semaines.

Enerpac Tool Group (NYSE:EPAC) Stock, Rapport sur les intérêts à découvert

Enerpac Tool Group

Enerpac Tool Group provides high-precision tools, controlled-force products, and solutions for precise heavy lifting. The company has one reportable segment, the Industrial Tools & Services (IT&S) Segment. The IT&S segment is primarily engaged in the design, manufacture, and distribution of branded hydraulic and mechanical tools and in providing services and tool rental to the refinery/petrochemical; general industrial; industrial maintenance, repair, and operations (MRO); machining & manufacturing; power generation; infrastructure; mining; and other markets. Geographically, the company has operations in Algeria, Australia, Brazil, France, Germany, Kazakhstan, India, Italy, Japan, Norway, Poland, Saudi Arabia, Singapore, South Africa, South Korea, Spain, and the United Arab Emirates.

Enerpac Tool Group Corp

WIIM

MRNA

Moderna shares are trading lower after JP Morgan maintained an Underweight rating on the stock and lowered its price target from $59 to $45.

NRG Energy shares are trading higher after Jefferies upgraded the stock from Hold to Buy and raised its price target from $93 to $113.

Investors with a lot of money to spend have taken a bullish stance on Archer Aviation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ACHR#NYSE">ACHR</a>).
And retail traders should know.
We noticed this today when the trades showed up on publicly available options history that we track here at Benzinga.
Whether these are institutions or just wealthy individuals, we don't know. But when something this big happens with ACHR, it often means somebody knows something is about to happen.
So how do we know what these investors just did? 
Today, <a href="https://pro.benzinga.com/?utm_source=insights">Benzinga</a>'s options scanner spotted 13 uncommon options trades for Archer Aviation.
This isn't normal.
The overall sentiment of these big-money traders is split between 76% bullish and 15%, bearish.
Out of all of the special options we uncovered, 2 are puts, for a total amount of $91,251, and 11 are calls, for a total amount of $386,385.
<h3>Projected Price Targets</h3>
After evaluating the trading volumes and Open Interest, it's evident that the major market movers are focusing on a price band between $2.0 and $10.0 for Archer Aviation, spanning the last three months.
<h3>Volume &amp; Open Interest Development</h3>
Looking at the volume and open interest is an insightful way to conduct due diligence on a stock.
This data can help you track the liquidity and interest for Archer Aviation's options for a given strike price.
Below, we can observe the evolution of the volume and open interest of calls and puts, respectively, for all of Archer Aviation's whale activity within a strike price range from $2.0 to $10.0 in the last 30 days. 
<h3>Archer Aviation Call and Put Volume: 30-Day Overview</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1732635071_0.png" alt="Options Call Chart" />
<h3>Significant Options Trades Detected:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th align="right">Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>ACHR</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>12/20/24</td>
<td>$1.25</td>
<td>$1.15</td>
<td>$1.2</td>
<td>$7.50</td>
<td>$61.2K</td>
<td>809</td>
<td align="right">530</td>
</tr>
<tr>
<td>ACHR</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>04/17/25</td>
<td>$2.8</td>
<td>$2.4</td>
<td>$2.8</td>
<td>$5.00</td>
<td>$56.0K</td>
<td>14.8K</td>
<td align="right">247</td>
</tr>
<tr>
<td>ACHR</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>11/29/24</td>
<td>$2.45</td>
<td>$2.35</td>
<td>$2.45</td>
<td>$5.00</td>
<td>$49.0K</td>
<td>2.0K</td>
<td align="right">204</td>
</tr>
<tr>
<td>ACHR</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>04/17/25</td>
<td>$2.15</td>
<td>$2.05</td>
<td>$2.15</td>
<td>$7.00</td>
<td>$42.9K</td>
<td>7.9K</td>
<td align="right">404</td>
</tr>
<tr>
<td>ACHR</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>01/15/27</td>
<td>$3.6</td>
<td>$3.3</td>
<td>$3.5</td>
<td>$7.00</td>
<td>$35.0K</td>
<td>4.1K</td>
<td align="right">64</td>
</tr>
</tbody>
</table>

<h3>About Archer Aviation</h3>
Archer Aviation Inc advances the benefits of sustainable air mobility. The company is engaged in designing and developing a fully electric vertical takeoff and landing eVTOL aircraft for use in UAM networks. It is creating an electric airline that moves people throughout cities in a quick, safe, sustainable, and cost-effective manner.
Following our analysis of the options activities associated with Archer Aviation, we pivot to a closer look at the company's own performance.
<h3>Current Position of Archer Aviation</h3>
<ul>
<li>Currently trading with a volume of 14,382,830, the ACHR's price is down by -2.94%, now at $7.26. </li>
<li>RSI readings suggest the stock is currently may be overbought.</li>
<li>Anticipated earnings release is in 90 days.</li>
</ul>
<h3>What The Experts Say On Archer Aviation</h3>
Over the past month, 1 industry analysts have shared their insights on this stock, proposing an average target price of $11.0.
Unusual Options Activity Detected: Smart Money on the Move
Benzinga Edge's Unusual Options board spots potential market movers before they happen. See what positions big money is taking on your favorite stocks. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22bz20&amp;utm_source=benzinga-insights">Click here for access</a>. 
&#x2A; In a cautious move, an analyst from Needham downgraded its rating to Buy, setting a price target of $11. 
Trading options involves greater risks but also offers the potential for higher profits. Savvy traders mitigate these risks through ongoing education, strategic trade adjustments, utilizing various indicators, and staying attuned to market dynamics. Keep up with the latest options trades for Archer Aviation with <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> for real-time alerts.

Options

Markets

ACHR

Archer Aviation Unusual Options Activity For November 26

ARWR

Arrowhead Pharmaceuticals shares are trading higher after the company entered into a global licensing and collaboration agreement with Sarepta Therapeutics for multiple clinical and preclinical siRNA programs.

Investors with a lot of money to spend have taken a bearish stance on Celsius Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CELH#NASDAQ">CELH</a>).
And retail traders should know.
We noticed this today when the trades showed up on publicly available options history that we track here at Benzinga.
Whether these are institutions or just wealthy individuals, we don't know. But when something this big happens with CELH, it often means somebody knows something is about to happen.
So how do we know what these investors just did? 
Today, <a href="https://pro.benzinga.com/?utm_source=insights">Benzinga</a>'s options scanner spotted 15 uncommon options trades for Celsius Holdings.
This isn't normal.
The overall sentiment of these big-money traders is split between 26% bullish and 60%, bearish.
Out of all of the special options we uncovered, 9 are puts, for a total amount of $427,399, and 6 are calls, for a total amount of $570,597.
<h3>Expected Price Movements</h3>
Taking into account the Volume and Open Interest on these contracts, it appears that whales have been targeting a price range from $15.0 to $130.0 for Celsius Holdings over the last 3 months. 
<h3>Insights into Volume &amp; Open Interest</h3>
Assessing the volume and open interest is a strategic step in options trading. These metrics shed light on the liquidity and investor interest in Celsius Holdings's options at specified strike prices. The forthcoming data visualizes the fluctuation in volume and open interest for both calls and puts, linked to Celsius Holdings's substantial trades, within a strike price spectrum from $15.0 to $130.0 over the preceding 30 days.
<h3>Celsius Holdings Option Activity Analysis: Last 30 Days</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1732635066_0.png" alt="Options Call Chart" />
<h3>Biggest Options Spotted:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th align="right">Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>CELH</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>09/19/25</td>
<td>$16.8</td>
<td>$15.5</td>
<td>$15.76</td>
<td>$15.00</td>
<td>$220.6K</td>
<td>184</td>
<td align="right">140</td>
</tr>
<tr>
<td>CELH</td>
<td>PUT</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>01/17/25</td>
<td>$101.8</td>
<td>$101.3</td>
<td>$101.75</td>
<td>$130.00</td>
<td>$101.7K</td>
<td>200</td>
<td align="right">20</td>
</tr>
<tr>
<td>CELH</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>01/17/25</td>
<td>$3.55</td>
<td>$3.4</td>
<td>$3.55</td>
<td>$28.33</td>
<td>$97.6K</td>
<td>1.3K</td>
<td align="right">309</td>
</tr>
<tr>
<td>CELH</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>01/16/26</td>
<td>$8.65</td>
<td>$8.6</td>
<td>$8.6</td>
<td>$30.00</td>
<td>$86.0K</td>
<td>5.0K</td>
<td align="right">233</td>
</tr>
<tr>
<td>CELH</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>01/16/26</td>
<td>$8.8</td>
<td>$8.75</td>
<td>$8.8</td>
<td>$30.00</td>
<td>$84.4K</td>
<td>5.0K</td>
<td align="right">97</td>
</tr>
</tbody>
</table>

<h3>About Celsius Holdings</h3>
Celsius Holdings plays in the energy drink subsegment of the global nonalcoholic beverage market, with 96% of revenue concentrated in North America. Celsius' products contain natural ingredients and a metabolism-enhancing formulation, appealing to fitness and active lifestyle enthusiasts. The firm's portfolio includes its namesake Celsius Originals beverages, Celsius Essentials line (containing aminos), and Celsius On-the-Go powder packets. Celsius dedicates its efforts to branding and innovation, while it utilizes third parties for the manufacturing, packaging, and distribution of its products. In 2022, Celsius forged a 20-year distribution agreement with PepsiCo, which holds an 8.5% stake in the business.
After a thorough review of the options trading surrounding Celsius Holdings, we move to examine the company in more detail. This includes an assessment of its current market status and performance.
<h3>Celsius Holdings's Current Market Status</h3>
<ul>
<li>With a volume of 1,720,788, the price of CELH is down -5.71% at $28.05. </li>
<li>RSI indicators hint that the underlying stock is currently neutral between overbought and oversold.</li>
<li>Next earnings are expected to be released in 93 days.</li>
</ul>
<h3>What The Experts Say On Celsius Holdings</h3>
5 market experts have recently issued ratings for this stock, with a consensus target price of $44.2.
Unusual Options Activity Detected: Smart Money on the Move
Benzinga Edge's Unusual Options board spots potential market movers before they happen. See what positions big money is taking on your favorite stocks. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22bz20&amp;utm_source=benzinga-insights">Click here for access</a>. 
&#x2A; An analyst from B. Riley Securities persists with their Buy rating on Celsius Holdings, maintaining a target price of $44. 
&#x2A; An analyst from Stifel has decided to maintain their Buy rating on Celsius Holdings, which currently sits at a price target of $45. 
&#x2A; An analyst from B. Riley Securities persists with their Buy rating on Celsius Holdings, maintaining a target price of $47. 
&#x2A; An analyst from Roth MKM has decided to maintain their Buy rating on Celsius Holdings, which currently sits at a price target of $40. 
&#x2A; An analyst from UBS persists with their Buy rating on Celsius Holdings, maintaining a target price of $45. 
Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating themselves, adapting their strategies, monitoring multiple indicators, and keeping a close eye on market movements. Stay informed about the latest Celsius Holdings options trades with real-time alerts from <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>.

CELH

Looking At Celsius Holdings's Recent Unusual Options Activity

Whales with a lot of money to spend have taken a noticeably bearish stance on Cava Group.
Looking at options history for Cava Group (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CAVA#NYSE">CAVA</a>) we detected 10 trades.
If we consider the specifics of each trade, it is accurate to state that 0% of the investors opened trades with bullish expectations and 60% with bearish.
From the overall spotted trades, 3 are puts, for a total amount of $159,975 and 7, calls, for a total amount of $260,023.
<h3>Expected Price Movements</h3>
Analyzing the Volume and Open Interest in these contracts, it seems that the big players have been eyeing a price window from $80.0 to $200.0 for Cava Group during the past quarter. 
<h3>Volume &amp; Open Interest Trends</h3>
Looking at the volume and open interest is an insightful way to conduct due diligence on a stock.
This data can help you track the liquidity and interest for Cava Group's options for a given strike price.
Below, we can observe the evolution of the volume and open interest of calls and puts, respectively, for all of Cava Group's whale activity within a strike price range from $80.0 to $200.0 in the last 30 days. 
<h3>Cava Group Option Volume And Open Interest Over Last 30 Days</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1732635061_0.png" alt="Options Call Chart" />
<h3>Largest Options Trades Observed:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th align="right">Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>CAVA</td>
<td>CALL</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>12/18/26</td>
<td>$58.9</td>
<td>$57.6</td>
<td>$58.25</td>
<td>$120.00</td>
<td>$58.2K</td>
<td>85</td>
<td align="right">10</td>
</tr>
<tr>
<td>CAVA</td>
<td>PUT</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>01/16/26</td>
<td>$40.1</td>
<td>$37.0</td>
<td>$38.65</td>
<td>$160.00</td>
<td>$57.9K</td>
<td>61</td>
<td align="right">15</td>
</tr>
<tr>
<td>CAVA</td>
<td>PUT</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>04/17/25</td>
<td>$33.1</td>
<td>$23.1</td>
<td>$27.6</td>
<td>$160.00</td>
<td>$55.2K</td>
<td>27</td>
<td align="right">0</td>
</tr>
<tr>
<td>CAVA</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>12/20/24</td>
<td>$6.3</td>
<td>$6.2</td>
<td>$6.2</td>
<td>$145.00</td>
<td>$55.1K</td>
<td>1.0K</td>
<td align="right">185</td>
</tr>
<tr>
<td>CAVA</td>
<td>PUT</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>02/21/25</td>
<td>$23.4</td>
<td>$23.4</td>
<td>$23.4</td>
<td>$160.00</td>
<td>$46.8K</td>
<td>7</td>
<td align="right">0</td>
</tr>
</tbody>
</table>

<h3>About Cava Group</h3>
Cava Group Inc owns and operates a chain of restaurants. It is the category-defining Mediterranean fast-casual restaurant brand, bringing together healthful food and bold, satisfying flavors at scale. The company's dips, spreads, and dressings are centrally produced and sold in grocery stores. The company's operations are conducted as two reportable segments: CAVA and Zoes Kitchen. The company generates the majority of its revenue from the CAVA segment.
Following our analysis of the options activities associated with Cava Group, we pivot to a closer look at the company's own performance.
<h3>Present Market Standing of Cava Group</h3>
<ul>
<li>With a trading volume of 306,516, the price of CAVA is down by -0.82%, reaching $141.37.</li>
<li>Current RSI values indicate that the stock is may be approaching overbought.</li>
<li>Next earnings report is scheduled for 91 days from now.</li>
</ul>
<h3>What The Experts Say On Cava Group</h3>
In the last month, 5 experts released ratings on this stock with an average target price of $153.6.
Turn $1000 into $1270 in just 20 days?
20-year pro options trader reveals his one-line chart technique that shows when to buy and sell. Copy his trades, which have had averaged a 27% profit every 20 days. <a href="https://www.benzinga.com/premium/ideas/options-moneyline-2/?t=Moop1arja3be22op14&amp;utm_source=benzinga-insights">Click here for access</a>. 
&#x2A; An analyst from TD Cowen has decided to maintain their Buy rating on Cava Group, which currently sits at a price target of $150. 
&#x2A; An analyst from Stifel persists with their Buy rating on Cava Group, maintaining a target price of $175. 
&#x2A; Consistent in their evaluation, an analyst from Citigroup keeps a Neutral rating on Cava Group with a target price of $163. 
&#x2A; Consistent in their evaluation, an analyst from Morgan Stanley keeps a Equal-Weight rating on Cava Group with a target price of $135. 
&#x2A; An analyst from Bernstein downgraded its action to Market Perform with a price target of $145. 
Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating themselves, adapting their strategies, monitoring multiple indicators, and keeping a close eye on market movements. Stay informed about the latest Cava Group options trades with real-time alerts from <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>.

CAVA

Behind the Scenes of Cava Group's Latest Options Trends

SRPT

Sarepta Therapeutics shares are trading higher after the company announced a global licensing and collaboration agreement with Arrowhead Pharmaceuticals for multiple clinical and preclinical siRNA programs.

Chevron shares are trading higher after Citigroup upgraded the stock from Neutral to Buy and raised its price target from $145 to $185.

<a href="https://www.aiaaic.org/aiaaic-repository/ai-algorithmic-and-automation-incidents/ftc-investigates-evolv-for-misleading-marketing" title="https://www.aiaaic.org/aiaaic-repository/ai-algorithmic-and-automation-incidents/ftc-investigates-evolv-for-misleading-marketing">https://www.aiaaic.org/aiaaic-repository/ai-algorithmic-and-automation-incidents/ftc-investigates-evolv-for-misleading-marketing</a>

News

EVLV

'The U.S. FTC Is Investigating Weapons Screening Firm Evolv Technologies Over Claims It Made About Its AI Systems Accurately Identifying Weapons Passing Through Its Screeners' - AIAAIC

On Monday, Alector, Inc.&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALEC#NASDAQ">ALEC</a>) released results from the INVOKE-2 Phase 2 trial evaluating the safety and efficacy of AL002 in slowing disease progression in individuals with <a target="_blank" href="https://www.benzinga.com/pressreleases/24/11/g42174676/alector-announces-results-from-al002-invoke-2-phase-2-trial-in-individuals-with-early-alzheimers-d" rel="noreferrer noopener">early Alzheimer&#8217;s disease (AD)</a>.
AL002 failed to meet the primary endpoint of slowing Alzheimer&#8217;s clinical progression as measured by the Clinical Dementia Rating Sum of Boxes (CDR-SB).
Also, no treatment effects favored AL002 on secondary clinical and functional endpoints.
The company says treatment with AL002 resulted in sustained target engagement and pharmacodynamic responses indicative of microglial activation.
Similarly, there were no significant effects on Alzheimer&#8217;s fluid biomarkers favoring AL002, and amyloid PET imaging demonstrated no treatment-related reduction of brain amyloid levels.
As previously reported, INVOKE-2 showed MRI changes resembling amyloid-related imaging abnormalities (ARIA) and infusion-related reactions. ARIA was primarily seen in participants treated with AL002.
Based on the results, Alector is stopping the long-term extension study.
Alector&#8217;s focus are progranulin-elevating programs, latozinemab, and AL101/GSK4527226, developed in collaboration with GSK Plc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GSK#NYSE">GSK</a>).
Topline data from the pivotal INFRONT-3 Phase 3 trial of latozinemab in frontotemporal dementia with a progranulin gene mutation is expected in late 2025 or early 2026.
PROGRESS-AD Phase 2 trial of AL101/GSK4527226 in early AD reached over one-third of its target enrollment of 282 participants. Alector is also advancing its preclinical candidates aimed at a broad and diverse range of protein and enzyme targets.
To align resources with these strategic priorities, Alector is reducing its workforce by approximately 17%.
As of September 30, 2024, Alector has $457.2 million in cash, cash equivalents, and investments, which the company continues to expect will provide a runway through 2026.
William Blair expressed surprise and disappointment at the update, given the strong scientific basis, evidence of target engagement, and potential signs of disease modification tied to ARIA cases. The analyst maintained the <a target="_blank" href="https://www.benzinga.com/quote/ALEC/analyst-ratings" rel="noreferrer noopener">Outperform rating.</a>
Despite still seeing promise in TREM2 as a target and in neuroinflammatory modulation, the firm is removing AL002 from its model due to the study&#8217;s failure, underscoring the difficulties in developing treatments for neurodegenerative diseases.
The analyst also expects AbbVie Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ABBV#NYSE">ABBV</a>) to opt out of the program partnership and forgo the potential <a target="_blank" href="https://www.benzinga.com/pressreleases/24/11/g41786512/alector-reports-third-quarter-2024-financial-results-and-provides-business-update" rel="noreferrer noopener">$250 million licensing payment</a>.
AbbVie has an exclusive option to develop and commercialize AL002 globally.
Price Action: ALEC stock is down 37.3% at $2.485 at last check Tuesday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/general/biotech/24/11/42190068/roches-proposed-acquisition-of-poseida-therapeutics-poised-to-establish-new-core-capability-in-cell-therapy-for-cancer-and-autoimmune-diseases-details" target="_blank" rel="noreferrer noopener">Roche&#8217;s Proposed Acquisition Of Poseida Therapeutics Poised To Establish New Core Capability In Cell Therapy For Cancer And Autoimmune Diseases: Details</a></li>
</ul>
Image via Shutterstock.

Analyst Color

Biotech

Equities

Health Care

Reiteration

Analyst Ratings

Movers

Trading Ideas

General

ABBV

ALEC

Alector/AbbVie-Partnered Alzheimer's Drug Disappoints In Mid-Stage Study; Alector Lays Off 17% Of Workforce

<a href="https://x.com/AvichayAdraee/status/1861428483966050423" title="https://x.com/AvichayAdraee/status/1861428483966050423">https://x.com/AvichayAdraee/status/1861428483966050423</a>

Macro Economic Events

Economics

iShares MSCI Israel Capped Investable Market Index Fund

Israeli Military Spokesman, Avichay Adraee, On X Issues Warning For Residents Near Hezbollah Facilities Targeted By IDF

Bernstein analyst Richard Clarke initiates coverage on Royal Caribbean Gr (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RCL#NYSE">RCL</a>) with a Outperform rating and announces Price Target of $290.

Price Target

Initiation

Bernstein Initiates Coverage On Royal Caribbean Gr with Outperform Rating, Announces Price Target of $290

We like to look at places that the rest of the world, especially Wall Street and all the instant experts on the Internet, are ignoring.
Right now, all eyes are on, and have been on, US markets.
The United States has gotten everything right over the past decade, and the rest of the planet has been, as Bogart used to lament, at least two drinks behind.
We recovered from both the Great Financial Crisis and COVID quicker, flooded the zone with cash from every imaginable source, and inflated lovely asset bubbles while Europe and Asia staggered along.
US markets went to the moon, while even the best foreign markets never broke free of gravity.
At the end of the GFC, US stocks were 41% of the global market, which has swelled to about 65% today.
The last time US stocks were this dominant, Lyndon Johnson was still in the White House, college kids were going &#8220;Clean for Gene&#8221; and Bobby Kennedy Sr. was mulling over a run for President.
William McChesney Martin Jr. was the Fed Chair, Gerry Tsai was the hottest fund manager, and Jamie Dimon turned 12 years old.
US stocks were all the rage and then delivered a whopping return of zero for the next 14 years, with several disastrous bear markets along the way.
The S&amp;P 500 (Ticker: SPY) lost about 4.5% a year on average.
International stocks outperformed US stocks by a dangerous margin, with a revitalized Japan leading the way higher.
That does not mean that it will happen again, right?
After all, we just elected a pro-business, low-tax President and interest rates will be moving lower.
Not only can it happen again, I would suggest it is likely to happen again.
I might also suggest you Google (Ticker: GOOGL) &#8220;Richard Nixon,&#8221; &#8220;Arthur Burns,&#8221; and &#8220;The Nifty Fifty&#8221; when you can.
The world loves the US stock market right now, and no one is considering Europe or Asia as investment opportunities.
That means that it is Under the Radar, and we are interested.
While economic growth outside the United States has been somewhat sluggish, this does not mean there has been zero growth.
Several companies have shown outstanding growth, and we want to start our international expedition in search of excess profits there.
My favorite growth measures are not earnings-related. It has long been my theory—and it holds up to rigorous testing—that the best growth measures are revenues and book value growth.
If revenues are high and cash has been reinvested in the business in a manner that grows the company&#8217;s net worth, that is sustainable growth.
A good accountant can make earnings appear to be whatever they desire, but the amount of stuff sold and the bottom-line net worth of the business are much harder to twist.
The income statement is the story, but the balance sheet is the finale.
Turkcell Iletisim Hizmetleri A.S. ADR (Ticker: TKC) is a great example of a sustainable growth company that is way off anyone&#8217;s radar screen. Turkey is hardly a hot topic of conversation around the water coolers of Wall Street or any other street in the United States.
Turkcell is a digital communication company operating in Belarus and Northern Cyprus. The company offers cell service, data, TV, and digital services over its network in its core markets.
It is growing like crazy, with revenues increasing by 42 percent annually over the past five years and the company&#8217;s value rising even faster, with book value rising by more than 60 percent a year.
The company is still in a hyper-growth phase with no signs of stopping.
The beauty of Turkcell lies in its ability to evolve. This is not your average telecom giant stuck in a rut of traditional services. Turkcell has embraced digital transformation with open arms, rolling out fintech solutions, digital subscriptions, and even cloud services. Couple this with its early investments in 5G, and you have a business poised to capture a huge slice of the digital economy in Turkey and surrounding countries.
Despite the noise around Turkey&#8217;s economic challenges, Turkcell has delivered consistent revenue growth and maintained fair profit margins. It is a cash-generating machine, and management has not forgotten about shareholders, doling out reliable dividends year after year. Add to that a valuation that is downright cheap compared to global peers, and you have a stock that ticks all the right boxes.
The stock has been moving higher but trades at a very reasonable valuation of just 15 times trailing earnings. If they come close to hitting this year&#8217;s earnings estimate, the stock will be trading at a single-digit P/E.
Growing earnings and an expanding multiple can create a wildly profitable combination in Turkcell shares for investors willing to look outside the United States for opportunities.
It is not always easy to be beautiful.
In fact, sometimes, it requires the help of surgeons and a collection of medical devices.
Many of these devices are made by InMode (Ticker: INMD), an Israeli company that manufactures minimally invasive technologies and devices for aesthetic repair and touch-ups without surgery, scars, or lasers.
This Israeli-based medical device company has carved out a sweet spot in the aesthetics industry with its minimally invasive and non-invasive body contouring and skin-tightening solutions.
InMode has built a reputation for delivering products that providers and patients love, and the financials prove it. The company boasts outstanding margins and a fortress-like balance sheet with zero debt and a growing pile of cash. Management has shown they know how to run a tight ship and are committed to rewarding shareholders, evidenced by their share buyback program.
The aesthetics market is not slowing down anytime soon, with growing demand fueled by rising disposable incomes and a global shift toward non-invasive beauty treatments. InMode&#8217;s innovative product pipeline keeps it ahead of competitors, ensuring a steady stream of revenue growth.
Over the last five years, sales have grown at over 30% annually, and InMode&#8217;s net worth is growing at almost 60% a year.
At its current valuation, InMode is a steal. You are getting a high-growth, high-margin business that throws off cash and operates in a market with tailwinds for years to come.
U.S. investors are ignoring the rest of the world.
Europe, in particular, is out of favor.
The economy is a mess. The stock markets are moribund.
The only rational choice is to start shopping for high-growth bargains and undervalued asset conversion opportunities (more on this next week)

Opinion

GOOGL

INMD

Under the Radar: From Overlooked to Overperforming - Global Markets Await

Hilton Grand Vacations shares are trading lower. Truist Securities cut its price target on the stock from $52 to $51.

Bernstein analyst Richard Jaffe initiates coverage on Carnival (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CCL#NYSE">CCL</a>) with a Market Perform rating and announces Price Target of $26.

Bernstein Initiates Coverage On Carnival with Market Perform Rating, Announces Price Target of $26

IPOs

CGTL

Creative Global Technology IPO Shares Open For Trade At $4.29/Share; IPO Priced at $4/Share On 1.25M Shares

UBS analyst Thomas Wadewitz assumes Southwest Airlines (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LUV#NYSE">LUV</a>) with a Sell rating and announces Price Target of $27.

UBS Assumes Southwest Airlines at Sell, Announces Price Target of $27

TBBB

BBB Foods shares are trading lower. The company reported Q3 financial results.

FLNC

Fluence Energy shares are trading lower after the company reported worse-than-expected Q4 sales results.

MDAI

Spectral AI Reprices  8,433,333 Public Warrants With An Exercise Price Of $11.50 Per Share To $2.75 Per Share; Expects To Receive Up To ~$23M In Net Proceeds

Biggest stock movers today: DJT, SEDG, EPAC and more

Enerpac Tool Group Corp. (EPAC) Q3 2024 Earnings Call Transcript

Earnings week ahead: PepsiCo, Delta Air Lines, JPMorgan, Citigroup and more

Enerpac Tool declares $0.04 dividend

Enerpac Tool Group: The Upside Might Be Fully Priced In

Enerpac Tool Group names Darren Kozik as CFO

Enerpac Tool Group ( ($EPAC) ) has issued an announcement. Enerpac Tool Group Corp. has appointed Darren M. Kozik as Executive Vice President and C...

Enerpac Tool Group Names New CFO Darren Kozik

Enerpac Tool Non-GAAP EPS of $0.50 misses by $0.03, revenue of $159M beats by $2.3M

Enerpac Tool Group Corp. (EPAC) Q4 2024 Earnings Call Transcript

BlackRock spotlights investment opportunities in Japan, China, and U.K.

AFAR

AIRE

ASHR

BBJP

BSET

BSVN

BYRN

CCEL

CHIQ

CNYA

CQQQ

CWEB

CXSE

DBJP

DJTWW

DXJS

EDUC

EPAC

ERIC

ETWO

EVGR

EWJV

EWUS

FAST

FLGB

FLJH

FLJP

FNGR

GDST

HELE

HEWJ

HIFS

JPXN

KLIP

KRUS

KWEB

LEDS

LEXX

MANU

MCHI

NRIX

NTIC

NVOS

PCYO

POOL

PSMT

SEDG

UPXI

VIST

VOXX

WDFC

XAIR

YANG

YINN

Earnings

Press Releases

Enerpac Tool Group Reports Third Quarter Fiscal 2024 Results

Management

Enerpac Tool Group Announces Eric Chack Appointed EVP – Operations

Dividends

Enerpac Tool Group Announces Dividend

Enerpac Tool Group Announces Acquisition of DTA

Enerpac Tool Group Schedules Fourth Quarter Fiscal 2024 Earnings Release and Conference Call

Enerpac Tool Group Announces Darren Kozik Appointed EVP & Chief Financial Officer

Enerpac Tool Group Reports Fourth Quarter and Full-Year Fiscal 2024 Results; Introduces Full-Year Fiscal 2025 Outlook

CORRECTION -- Enerpac Tool Group Reports Fourth Quarter and Full-Year Fiscal 2024 Results; Introduces Full-Year Fiscal 2025 Outlook

STRATTEC SECURITY CORPORATION Appoints Matthew Pauli as Chief Financial Officer Effective November 13, 2024

Argus Research Initiates Equity Research Report Coverage on Enerpac Tool Group Corp. (NYSE: EPAC).

Comments

Enerpac Tool Group

Intérêt court

Enerpac Tool Group (NYSE:EPAC) Stock, Rapport sur les intérêts à découvert

Les gens regardent aussi

Notizie

PARTENAIRE / CONTRIBUTEUR

BENZINGA MONDIAL